ReviewAmerican journal of clinical dermatology2021
Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment.
Review in American journal of clinical dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Tumor-infiltrating lymphocyte therapy in metastatic vulvar melanoma: A case report and review of the literature.Gynecologic oncology reports · 2026Article
- Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Temporal Trends in Vulvar Cancer Cases and Associated Factors of Adverse Clinical Features: A 6-year Retrospective Study From a Tertiary Hospital in Indonesia.International journal of women's health · 2026Article
- Vulvar malignant melanoma versus vaginal malignant melanoma: distinct biology, distinct clinical behavior, and distinct management?Frontiers in oncology · 2026Review
- Web-based predictive tool for vaginal and vulvar melanomas: a machine learning study.Future science OA · 2025Article
- Review
- Comparative Insights into Cutaneous, Mucosal, and Vulvovaginal Melanomas: Biology, Targeted Therapies, and Survival with a Focus on Immune Checkpoint Inhibitors.Journal of personalized medicine · 2025Review
- Bibliometric analysis of global research trends in delivery systems for breast cancer immunotherapy.Discover oncology · 2025Article
- Pancreatic Metastasis From a Vulvar Melanoma Diagnosed by Endoscopic Ultrasound-Guided Fine-Needle Biopsy.ACG case reports journal · 2025Article
- Pulsed electric field (PEF) treatment of refractory vulvar melanoma concurrently treated with immune checkpoint blockade demonstrating an abscopal response: A case report.Gynecologic oncology reports · 2025Article
- Diagnosis and treatment of 33 patients with primary melanoma of the female reproductive system.Frontiers in oncology · 2025Article
- Immune checkpoint inhibitor outcomes and prognostic factors in gynecologic tract melanoma: a single-center analysis.Frontiers in immunology · 2025Article
- Multidisciplinary Vulvar Cancer Management: The Dermatologist's Perspective.Life (Basel, Switzerland) · 2024Review
- Robot-assisted laparoscopic hepatectomy for liver metastasis from clitoral malignant melanoma: a case report.Surgical case reports · 2024Article
- Treatment outcomes of vulvar and vaginal melanoma at an NCCN institution between 1993 and 2021.Gynecologic oncology reports · 2024Article
- Full-body skin examination in screening for cutaneous malignancy: A focus on concealed sites and the practices of international dermatologists.JEADV clinical practice · 2024Article
- Primary vulval melanoma and genital lichen sclerosus.Skin health and disease · 2024Article
- From Lipid Signatures to Cellular Responses: Unraveling the Complexity of Melanoma and Furthering Its Diagnosis and Treatment.Medicina (Kaunas, Lithuania) · 2024Review
- A Rare Case of Invasive Malignant Melanoma Metastasis in the Vulvar Mucosa 11 Years After Diagnosis and Treatment.Cureus · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Ten percent of all women have pigmented vulvar lesions. Fortunately, most of these are benign but 1% of all melanomas in women affect the vulva. While the mortality rate of cutaneous melanoma has dropped by 7% annually during the last 5 years, the prognosis of vulvar melanoma remains dismal: the 5-year overall survival rate is 47% compared with 92% for cutaneous melanoma. The current evidence suggests that this likely results from a combination of delayed diagnosis and different tumor biology, treatment strategies, and treatment response. Although many landmark trials on checkpoint inhibitors included mucosal and vulvar melanomas, the results were often not reported separately. Post-hoc analyses indicate overall response rates between 19 and 37% for checkpoint inhibitors. A recently published retrospective study on vulvar melanomas suggests an objective response in 33.3% with a similar safety profile to cutaneous melanoma. Tyrosine kinase inhibitors may be considered in recurrent disease if a c-KIT mutation is present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.